<p><strong><span class="legendSpanClass"><span class="xn-location">CUPERTINO </span>and <span class="xn-location">MUMBAI, India </span></span></strong>&#8212; <u><a href="https://c212.net/c/link/?t=0&;l=en&;o=4308165-1&;h=1175823305&;u=https%3A%2F%2Fwww.onecelldx.com%2F&;a=OneCell+Diagnostics" target="_blank" rel="nofollow noopener">OneCell Diagnostics</a></u>, a genomics-based precision oncology company, has raised $16 million in an oversubscribed Series A funding round led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. The funding will be used to advance its vision of democratizing precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable. Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. <span class="xn-person">James Rothman</span> will join the OneCell board of directors.</p>
<p>OneCell has developed cutting-edge technology for precision oncology liquid biopsy diagnostics. Their cancer screening tests are based on a proprietary Circulating Tumor Cell (CTC) and True-Single-Cell-Multi-omics platform, supporting a range of applications in clinical cancer care and early-stage clinical trials for biotech and pharma companies. OneCell&#8217;s cell biopsy technology integrates CTC-DNA with CTC-RNA and cell surface protein testing, all from a single blood draw, a significant advancement over current &#8220;liquid biopsy&#8221; testing.</p>
<p>&#8220;We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,&#8221; said <span class="xn-person">Mohan Uttarwar</span>, CEO and Co-founder at OneCell Diagnostics. &#8220;By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalized cancer care worldwide.&#8221;</p>
<p>With this Series A funding, OneCell will expand to the U.S. market with its next-generation liquid biopsy test, OncoIndx Ikon. The test detects and analyzes CTCs, which offer rich biomarkers that advance precision diagnosis and treatment of cancer for use cases including treatment response monitoring, disease progression, recurrence, and more. Through its global operations in Silicon Valley and in <span class="xn-location">India</span>, the company has already introduced a range of products in <span class="xn-location">India</span>, where it has tested nearly ten thousand patients to date and demonstrated that its cell biopsy technology can be implemented easily, safely, and cost-effectively at any lab worldwide. The company&#8217;s growing list of strategic academic and industry partners include <span class="xn-org">Harvard Medical School</span>, <span class="xn-org">Stanford University</span>, and other leading medical institutions.</p>
<p>&#8220;Celesta is excited about differentiated companies sitting at the intersection of high tech and biomedical science, and OneCell fits this mold perfectly,&#8221; said <span class="xn-person">Michael Marks</span>, Founding Managing Partner at Celesta Capital. &#8220;By leveraging the strategic benefits of the U.S. &#8211; <span class="xn-location">India</span> corridor, OneCell is well-positioned to continue building competitive advantages. We pride ourselves on being active value-add investors and Celesta will tap our ecosystem to support their growth wherever possible.&#8221;</p>
<p>&#8220;I&#8217;m looking forward to joining the OneCell Board at such a pivotal time in the arc of innovation for cancer treatment,&#8221; said Dr. <span class="xn-person">James Rothman</span>, Nobel Laureate and Celesta Capital Advisor. &#8220;Cell biopsy represents a groundbreaking shift in how we approach diagnostics, creating more opportunities for highly individualized care. This technology has the potential to reshape the oncology landscape, and we are eager to support OneCell&#8217;s bold mission to reach more than 1000 oncologists and 1 million patients in the near future.&#8221;</p>

MOUNTAIN VIEW - Intuit Inc., operator of the financial technology platform that makes Intuit TurboTax, Credit Karma, QuickBooks,…
The Santa Clara County District Attorney’s Office has charged a Sunnyvale apartment manager with possessing…
SAN FRANCISCO -- Wispr, the voice-to-text AI that turns speech into clear, polished writing in every…
SAN FRANCISCO -- Numeric, an AI accounting automation platform, has raised a $51 million Series…
Apple has announced 45 finalists for this year’s App Store Awards, recognizing the best apps…
The University of California (UC) and the California Nurses Association (CNA) have reached a tentative…